Group 1: Company Overview - The company is Hunan Jiudian Pharmaceutical Co., Ltd., with stock code 300705 and bond code 123223 [1][2]. Group 2: Investor Relations Activity - The investor relations activity took place on November 27, 2023, from 10:00 to 11:30 AM in the company meeting room [2]. - The meeting was attended by representatives from Huazhong Medicine and included a Q&A format to address investor inquiries [2]. Group 3: Business Model and Sales Performance - The company is transitioning to a semi-self-operated model, which aims to improve operational efficiency and profitability through refined management [2]. - As of the third quarter of this year, the sales proportion of the semi-self-operated model for the product Loxoprofen Sodium Gel Patch in Henan, Shandong, and Hunan provinces exceeded 10% [2]. Group 4: Market Insights - The Loxoprofen Sodium Gel Patch has a higher sales proportion in regions such as Beijing, Zhejiang, Shanghai, Guangdong, and Sichuan [3]. - The product won a bid in the Guangdong Alliance region last year at a price of 18.19 yuan per patch, with good execution observed in Guangdong and Henan provinces [3]. - A recent bid in Zhejiang Province was won at a price of 17.37 yuan per patch, which is expected to expand the product's sales range and enhance market share [3]. Group 5: Product Development and Competition - The Pepper Seven Musk Gel Patch is expected to be submitted for production approval by the end of this year, with a projected approval in 2025, focusing on hospital channels for sales [3]. - Data from Yao Rongyun indicates that the compound annual growth rate (CAGR) for chemical drug patches in hospitals over the past three years is approximately 24.22%, while traditional Chinese medicine patches have a CAGR of about 5.59% [3].

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2023-32 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 国元证券 人员姓名 时间 2023年11 月17日下午13:30-15:00 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、酮洛芬凝胶贴膏和洛索洛芬钠凝胶贴膏是否会形成竞争 关系？ 回复：从外用抗炎镇痛药物的市场竞争格局来讲，目前化 ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2023-31 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 永安国富 人员姓名 时间 2023 年 11月 10 日上午10:00-11:30 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 证券事务代表：甘荣 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、请简单介绍下公司的发展历程和业务分布情况？ 回复：公司成立于2001 年 1月，2017 年 10 月在创业板 上市，目前已发展成为集医药研发、生产和销售于一体，在药 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2023-067 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 品种 名称 注册 分类 适应症 规格 拟中选 价格 拟中选数量 拟主供 供应省份 拟备供 供应省份 乙酰半胱 氨酸颗粒 化药 4 适用于慢性支 气管炎等咳嗽 有黏痰而不易 咳出的患者。 0.1g×46 包/盒 22.54 元 /盒 5,064.0356 万包 广东、四川、 江西、云南、 上海、天津、 新疆（含兵 团） 福建、湖南、 重庆、河北、 黑龙江、北 京、内蒙古 雷贝拉唑 钠肠溶片 化药 4 胃溃疡、十二 指肠溃疡、吻 合口溃疡、反 流性食管炎、 卓一艾氏 (Zollinger-E llison)综合 征。辅助用于 胃溃疡或十二 指肠溃疡患者 根除幽门螺旋 杆菌。 10mg×28 片/盒 7.18 元/ 盒 2,988.7565 万片 山东、湖北、 甘肃、西藏 安徽、陕西、 新疆(含兵 团)、青海 一、拟中选品种基本情况 售收入为 1,494.12 万元，占公司同期营业收入的 0.79%。 公司产品雷贝拉唑钠肠溶片于 ...

Product Portfolio and Development - The company's main products include Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, with several other products in the pipeline such as Lidocaine Gel Patch, Lidocaine and Prilocaine Cream, Indomethacin Gel Patch, and Flurbiprofen Gel Patch [3] - The company is focusing on developing a range of anti-inflammatory and analgesic products in the transdermal drug delivery field to create a robust product lineup and enhance the brand value of "Jiuyue" patches [3] Market and Sales Strategy - The company's gel patch products are maintaining growth due to strong market demand in the anti-inflammatory and analgesic sector, with chronic pain affecting 24.9% of the population globally and 8.91% in urban China (e.g., Beijing) [4] - The company is transitioning to a semi-self-operated model, which improves operational efficiency and profitability by shifting from result-oriented management to process-oriented management [4] - Plans are in place to optimize the sales team structure and personnel allocation for the next year, including expanding the KA team, increasing the sales promotion team, and strengthening the commercial team to prepare for the semi-self-operated model [4] Regulatory and Technical Barriers - The gel patch sector faces significant barriers, including technical challenges in maintaining a stable drug release system and ensuring consistent drug penetration rates, as well as a lengthy regulatory approval process involving R&D, clinical trials, and market approval [3] Regional Market Execution - The company's Loxoprofen Sodium Gel Patch has been included in the Guangdong Alliance regional procurement, with execution already underway in seven regions: Shanxi, Guangdong, Qinghai, Hainan, Henan, Xinjiang Uygur Autonomous Region, and Ningxia Hui Autonomous Region [2]

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2023-29 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 其他2023年湖南辖区上市公司投 资者网上集体接待日活动 参与单位名称及 参加2023年湖南辖区上市公司投资者网上集体接待日活动的 人员姓名 全体投资者 时间 2023年11 月2日下午15:00-17:00 地点 全景路演（https://rs.p5w.net） 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 证券事务代表：甘荣 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、尊敬的领导，下午好！希望和公司领导交流一下：（1）公 司新发行 3.6 亿元可转债募投项目最新进展？（2）作为个人 ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2023-28 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 申万菱信基金 东方财富证券 君汇私募 人员姓名 雷沃基金 华企航（深圳）投资基金 2023年11 月1日上午9:00-10:15 时间 2023年11 月1日下午16:30-17:30 地点 公司会议室 上市公司接待人 副总经理兼董事会秘书：曾蕾 员姓名 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、能否先简单介绍下公司基本情况和实际控制人的基本情 况？ ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2023-066 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | | 股东 | 是否为第一 | | 本次质押可 | 占其所 | 占公司可 | 是否为 | 质押 | 质押 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及一 | | 转债数量 | 持可转 | 转债比例 | 补充质 | 开始日期 | 到期日 | 质权人 | 用途 | | | 致行动人 | | （张） | 债比例 | | 押 | | | | | | 朱志宏 | | 是 | 1,227,720 | 100.00% | 34.10% | 否 | 2023-10-30 | 办理解 除质押 | 云南国际 信托有限 | 个人 | | | | | | | | | | 登记手 | | 融资 | | | | | | | | | | 续之日 | 公司 | | | | | | | | | | | 办理解 除质押 | 云南国 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2023-065 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）及全资子公司湖南普道医 药技术有限公司（以下简称"普道医药"）于近日各收到 1 份国家药品监督管理 局下发的《药品注册证书》。现将相关情况公告如下： 一、 证书的主要内容 （一）药品注册证书 1 1、药品名称：非洛地平片 2、剂型：片剂 3、规格：2.5mg 4、注册分类：化学药品 3 类 5、申请事项：药品注册（境内生产） 6、证书编号：2023S01619 7、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 8、上市许可持有人：湖南九典制药股份有限公司 （二）药品注册证书 2 1、药品名称：洛索洛芬钠口服溶液 2、剂型：口服溶液剂 3、规格：10ml ...

Financial Performance - In Q3 2023, the company achieved a revenue of 6.75 billion CNY, representing a year-on-year growth of 18.83% [2] - For the first three quarters of 2023, the total revenue reached 18.93 billion CNY, with a year-on-year increase of 48.76% [2] - The net profit attributable to shareholders for Q3 2023 was 1.12 billion CNY, up 42.91% compared to the previous year [3] - The net profit attributable to shareholders for the first three quarters was 3.10 billion CNY, reflecting a growth of 43.24% [2] Business Segment Performance - The pharmaceutical formulation segment generated sales of 15.92 billion CNY in the first three quarters, with a growth of 20.02% [3] - The leading product, Loxoprofen Sodium Gel Patch, achieved sales of 10.98 billion CNY, marking a year-on-year increase of 22.71% [3] - In Q3 2023, the pharmaceutical formulation segment's revenue was 5.83 billion CNY, up 21.58% [3] - The raw materials segment reported sales of 96.68 million CNY, with an increase of 11.07% [3] Market Development - The company successfully developed 220 chain stores in the outpatient market for Loxoprofen Sodium Gel Patch, covering over 35,000 stores [3] - The pricing for the outpatient market remains consistent with the inpatient market [4] - The company is optimizing its sales team structure and plans to expand its KA team and business team for future growth [4] Market Trends - The external patch market in 2022 was approximately 18.4 billion CNY, with a growth rate of around 20% [5] - Chemical drug patches have shown a compound annual growth rate (CAGR) of 24.22% in hospitals over the past three years, indicating significant growth potential [5] - The company expresses confidence in the sales potential of Loxoprofen Sodium Gel Patch due to the large market space [5] Product Development - The company is currently working on several external preparation products, including Lidocaine Gel Patch and Loxoprofen Sodium Gel Patch, which have been submitted for production [6] - Clinical trials are ongoing for other products such as Indomethacin Gel Patch and Fluorobufen Gel Patch [6]